99mTc-hydrazinonicotinamide epidermal growth factor-polyethylene glycol-quantum dot imaging allows quantification of breast cancer epidermal growth factor receptor expression and monitors receptor downregulation in response to cetuximab therapy

Journal of Nuclear Medicine

Volumn 52, Issue 9, 2011, Pages 1457-1464

  Jung, Kyung Ho ^a   Choe, Yearn Seong ^a   Paik, Jin Young ^a   Lee, Kyung Han ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

Breast cancer; Epidermal growth factor receptor; Molecular imaging; Oncology; Scintigraphy

Indexed keywords

CETUXIMAB; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; HYDRAZINONICOTINAMIDE TC 99M; MACROGOL; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; DIAGNOSTIC AGENT; MACROGOL DERIVATIVE; MONOCLONAL ANTIBODY; QUANTUM DOT; TECHNETIUM COMPLEX;

ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; BINDING ASSAY; BREAST CANCER; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CORRELATION ANALYSIS; DOWN REGULATION; DRUG DISTRIBUTION; DRUG RESPONSE; FEMALE; HUMAN; HUMAN CELL; IMAGING; IMMUNOBLOTTING; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PHENOTYPE; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTUM DOT IMAGING; SCINTIGRAPHY; TUMOR XENOGRAFT; ANIMAL; BREAST TUMOR; DRUG EFFECT; DRUG SCREENING; METABOLISM; SCINTISCANNING; TISSUE DISTRIBUTION; TRANSMISSION ELECTRON MICROSCOPY; TUMOR CELL LINE; WESTERN BLOTTING;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL LINE, TUMOR; DOWN-REGULATION; EPIDERMAL GROWTH FACTOR; FEMALE; HUMANS; MICE; MICROSCOPY, CONFOCAL; MICROSCOPY, ELECTRON, TRANSMISSION; ORGANOTECHNETIUM COMPOUNDS; POLYETHYLENE GLYCOLS; QUANTUM DOTS; RADIOPHARMACEUTICALS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TISSUE DISTRIBUTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 80052617785     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.111.087619     Document Type: Article

References (35)

1. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2001;2:127-137. (Pubitemid 33674041)
2. Arteaga CL. The epidermal growth factor receptor: from mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia. J Clin Oncol. 2001;19(18 suppl):32S-40S. (Pubitemid 32880077)
3. Sainsbury JR, Farndon JR, Needham GK, Malcolm AJ, Harris AL. Epidermal-growth- factor receptor status as predictor of early recurrence of and death from breast cancer. Lancet. 1987;1:1398-1402. (Pubitemid 17078859)
4. Siena S, Sartore-Bianchi A, Di Nicolantonio F, Balfour J, Bardelli A. Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer. J Natl Cancer Inst. 2009;101:1308-1324.
5. Baselga J, Arteaga CL. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J Clin Oncol. 2005;23:2445-2459. (Pubitemid 47050835)
6. Bossuyt V, Fadare O, Martel M, et al. Remarkably high frequency of EGFR expression in breast carcinomas with squamous differentiation. Int J Surg Pathol. 2005;13:319-327. (Pubitemid 41688593)
7. Pawlowski V, Révillion F, Hebbar M, Hornez L, Peyrat JP. Prognostic value of the type I growth factor receptors in a large series of human primary breast cancers quantified with a real-time reverse transcription-polymerase chain reaction assay. Clin Cancer Res. 2000;6:4217-4225.
8. Gao XP, Liu F. New agents in development for breast cancer. Curr Opin Obstet Gynecol. 2007;19:68-74. (Pubitemid 46095876)
9. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 2001;98:10869-10874. (Pubitemid 32878711)
10. Da Silva L, Clarke C, Lakhani SR. Demystifying basal-like breast carcinomas. J Clin Pathol. 2007;60:1328-1332. (Pubitemid 350247248)
11. Livasy CA, Karaca G, Nanda R, et al. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol. 2006;19:264-271. (Pubitemid 43117611)
12. Flynn JF, Wong C, Wu JM. Anti-EGFR therapy, mechanism and advances in clinical efficacy in breast cancer. J Oncol. 2009;2009:526963.
13. Neve RM, Chin K, Fridlyand J, et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell. 2006;10:515-527. (Pubitemid 44854747)
14. Lee H, Jang IH, Ryu SH, Park TG. N-terminal site-specific mono-PEGylation of epidermal growth factor. Pharm Res. 2003;20:818-825. (Pubitemid 36515317)
15. Guide for the Care and Use of Laboratory Animals. Bethesda, MD: National Institutes of Health; 1985. NIH publication 85-23.
16. Rose WC, Wild R. Therapeutic synergy of oral taxane BMS-275183 and cetuximab versus human tumor xenografts. Clin Cancer Res. 2004;10:7413-7417. (Pubitemid 39487730)
17. Euhus DM, Hudd C, LaRegina MC, Johnson FE. Tumor measurement in the nude mouse. J Surg Oncol. 1986;31:229-234. (Pubitemid 16104025)
18. Weissleder R, Pittet MJ. Imaging in the era of molecular oncology. Nature. 2008;452:580-589. (Pubitemid 351483372)
19. Mankoff DA, Sullivan FO, Barlow WE, Krohn KA. Molecular imaging research in the outcomes era: measuring outcomes for individualized cancer therapy. Acad Radiol. 2007;14:398-405. (Pubitemid 46401412)
20. Maecke HR. Radiolabeled peptides in nuclear oncology: influence of peptide structure and labeling strategy on pharmacology. Ernst Schering Res Found Workshop. 2005;49:43-72.
21. Liu S. Bifunctional coupling agents for radiolabeling of biomolecules and target-specific delivery of metallic radionuclides. Adv Drug Deliv Rev. 2008;60:1347-1370.
22. Michalet X, Pinaud FF, Bentolila LA, et al. Quantum dots for live cells, in vivo imaging, and diagnostics. Science. 2005;307:538-544. (Pubitemid 40165671)
23. Gao X, Cui Y, Levenson RM, Chung LW, Nie S. In vivo cancer targeting and imaging with semiconductor quantum dots. Nat Biotechnol. 2004;22:969-976. (Pubitemid 39014473)
24. Tada H, Higuchi H, Wanatabe TM, Ohuchi N. In vivo real-time tracking of single quantum dots conjugated with monoclonal anti-HER2 antibody in tumors of mice. Cancer Res. 2007;67:1138-1144.
25. Hardman R. A toxicologic review of quantum dots: toxicity depends on physicochemical and environmental factors. Environ Health Perspect. 2006;114:165-172. (Pubitemid 43193634)
26. Schipper ML, Cheng Z, Lee SW, et al. MicroPET-based biodistribution of quantum dots in living mice. J Nucl Med. 2007;48:1511-1518. (Pubitemid 47397401)
27. Cai W, Shin DW, Chen K, et al. Peptide-labeled near-infrared quantum dots for imaging tumor vasculature in living subjects. Nano Lett. 2006;6:669-676.
28. Owens DE 3rd, Peppas NA. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int J Pharm. 2006;307:93-102. (Pubitemid 41773257)
29. Schipper ML, Iyer G, Koh AL, et al. Particle size, surface coating, and PEGylation influence the biodistribution of quantum dots in living mice. Small. 2009;5:126-134.
30. Manning HC, Merchant NB, Foutch AC, et al. Molecular imaging of therapeutic response to epidermal growth factor receptor blockade in colorectal cancer. Clin Cancer Res. 2008;14:7413-7422.
31. Wang K, Wang K, Li W, et al. characterizing breast cancer xenograft epidermal growth factor receptor expression by using near-infrared optical imaging. Acta Radiol. 2009;50:1095-1103.
32. Ke S, Wen X, Gurfinkel M, et al. Near-infrared optical imaging of epidermal growth factor receptor in breast cancer xenografts. Cancer Res. 2003;63:7870-7875. (Pubitemid 37466721)
33. Diagaradjane P, Orenstein-Cardona JM, Colón-Casasnovas NE, et al. Imaging epidermal growth factor receptor expression in vivo: pharmacokinetic and biodistribution characterization of a bioconjugated quantum dot nanoprobe. Clin Cancer Res. 2008;14:731-741. (Pubitemid 351231154)
34. Perez-Torres M, Guix M, Gonzalez A, Arteaga CL. Epidermal growth factor receptor (EGFR) antibody down-regulates mutant receptors and inhibits tumors expressing EGFR mutations. J Biol Chem. 2006;281:40183-40192. (Pubitemid 46041823)
35. Oliveira S, Schiffelers RM, Van der Veeken J, et al. Downregulation of EGFR by a novel multivalent nanobody-liposome platform. J Control Release. 2010;145:165-175.